Immune Regulation of Postoperative Fibrosis: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Abstract

Postoperative fibrosis is a significant complication following surgery, affecting tissue function, healing, and patient outcomes. Over the last decade, increasing evidence has highlighted the central role of immune regulation in the development and progression of fibrotic changes after surgical interventions. This review synthesizes current knowledge on the epidemiology, pathophysiological mechanisms, risk factors, clinical features, diagnostic approaches, and management of postoperative fibrosis, with an emphasis on the immunological underpinnings. Recent advances in immunomodulatory therapies and evidence-based guidelines are discussed to provide a comprehensive resource for clinicians and researchers involved in perioperative care and the prevention of adverse fibrotic outcomes.

Introduction

Postoperative fibrosis refers to the excessive deposition of extracellular matrix and connective tissue following surgical injury, leading to scar formation and sometimes pathological sequelae such as adhesions, contractures, and organ dysfunction. While fibrosis is a natural component of wound healing, dysregulation of immune responses can transform this process into a maladaptive one. Understanding the immunological mechanisms driving postoperative fibrosis is crucial for developing targeted interventions and improving patient prognosis. This article aims to provide an in-depth review of immune-mediated regulation of postoperative fibrosis, drawing upon recent research and clinical guidelines to inform contemporary surgical practice.

Epidemiology / Disease Burden

Postoperative fibrosis is a common yet under-recognized complication across surgical specialties. Incidence rates vary depending on surgical site, technique, and patient factors. For example, intra-abdominal adhesions occur in up to 93% of patients after open abdominal surgery, contributing to chronic pain, infertility, and intestinal obstruction. In orthopedic procedures, joint contractures and peritendinous fibrosis can compromise mobility and function. Fibrotic complications significantly prolong hospital stay, increase healthcare costs, and adversely impact quality of life. The true burden is likely underestimated due to variability in reporting and lack of standardized diagnostic criteria. Multi-institutional studies are ongoing to better quantify the epidemiological impact and identify high-risk populations.

Pathophysiology

Fibrosis is orchestrated by a complex interplay between immune cells, cytokines, and resident stromal cells. Immediately following tissue injury, innate immune responses trigger the recruitment of neutrophils and macrophages, which clear debris and orchestrate initial inflammation. Macrophage polarization toward a pro-fibrotic (M2) phenotype leads to the secretion of transforming growth factor-beta (TGF-β), interleukin-13 (IL-13), and connective tissue growth factor (CTGF), all of which promote fibroblast activation and differentiation into myofibroblasts. Myofibroblasts are key effectors of extracellular matrix (ECM) deposition, leading to tissue stiffening and scar formation. Dysregulation of T regulatory cells (Tregs), Th17 cells, and a persistent inflammatory milieu can perpetuate the fibrotic cascade. Recent studies have also implicated the role of damage-associated molecular patterns (DAMPs) and innate lymphoid cells (ILCs) in modulating the fibrotic response, suggesting new avenues for therapeutic intervention.

Risk Factors

Several patient- and procedure-related factors contribute to the risk of postoperative fibrosis. Patient-related risks include advanced age, diabetes mellitus, autoimmune disorders, genetic predisposition (e.g., polymorphisms in TGF-β1 gene), and previous history of keloid or hypertrophic scar formation. Procedure-related factors encompass the extent of tissue dissection, inadequate hemostasis, infection, foreign body implantation (such as mesh or prosthesis), and prolonged or repeated surgeries. Immunological risk factors, such as pre-existing chronic inflammation or altered immune status due to immunosuppression or chemotherapy, may further predispose individuals to aberrant fibrotic responses. Identification and modification of these risk factors are integral to the prevention and management of postoperative fibrosis.

Clinical Features

Clinical manifestations of postoperative fibrosis are heterogeneous and depend on the anatomical site involved. Patients may present with persistent pain, restricted mobility, palpable masses, or signs of organ dysfunction. Intra-abdominal fibrosis can cause bowel obstruction, while periarticular fibrosis leads to joint stiffness. In severe cases, fibrotic tissue may compromise vital structures, resulting in neurovascular compression or impaired organ perfusion. Subclinical fibrosis is often detected incidentally on imaging or during reoperation. Timely recognition of characteristic clinical features is essential for prompt intervention and mitigation of long-term sequelae.

Diagnosis

Diagnosis of postoperative fibrosis integrates clinical assessment with imaging and, occasionally, histopathological evaluation. Modalities such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) provide valuable information on the location, extent, and density of fibrotic tissue. Elastography and diffusion-weighted MRI offer non-invasive quantification of tissue stiffness and may help in monitoring disease progression. In select cases, tissue biopsy is warranted to exclude recurrent malignancy or infectious etiologies. Emerging biomarkers, including circulating TGF-β, matrix metalloproteinases (MMPs), and microRNAs, are under investigation for their potential utility in early detection and risk stratification.

Treatment & Management

Management of postoperative fibrosis requires a multifaceted approach tailored to the site and severity of involvement. Conservative measures include physiotherapy, anti-inflammatory medications, and pain management. In cases of significant functional impairment, surgical intervention such as adhesiolysis or contracture release may be indicated. The use of barrier agents (e.g., hyaluronic acid-based products) during surgery has shown efficacy in reducing adhesion formation. Immunomodulatory therapies, notably corticosteroids and off-label use of agents such as methotrexate and tamoxifen, have demonstrated benefit in select patient populations, though evidence remains mixed. Close multidisciplinary collaboration is essential to optimize outcomes and minimize recurrence.

Recent Advances / Emerging Therapies

Recent years have witnessed the development of innovative strategies targeting immune pathways involved in fibrogenesis. Monoclonal antibodies against TGF-β, IL-13, and other profibrotic cytokines are in various stages of clinical development. Small molecule inhibitors of lysyl oxidase-like 2 (LOXL2) and integrins have shown promise in preclinical models. Cell-based therapies, including the adoptive transfer of Tregs or mesenchymal stem cells (MSCs), aim to restore immune homeostasis and promote regenerative healing. The application of RNA-based therapeutics and gene editing tools offers new possibilities for precise modulation of fibrotic gene expression. Although these advances are encouraging, further large-scale trials are required to establish safety, efficacy, and long-term benefit.

Guideline Recommendations

Current clinical guidelines emphasize the importance of meticulous surgical technique, judicious use of foreign materials, and optimal perioperative care to minimize fibrotic complications. Prophylactic interventions, such as barrier agents and early mobilization, are recommended for high-risk patients. The use of immunosuppressive or antifibrotic pharmacotherapy should be individualized based on risk stratification and comorbidities. Ongoing surveillance and early intervention are crucial for patients with established fibrosis. Multidisciplinary management involving surgeons, immunologists, rehabilitation specialists, and pain teams is advocated to address the complex needs of affected individuals. Updated guidelines from specialty societies continue to evolve as new evidence emerges.

Conclusion

The immune system plays a pivotal role in the regulation of postoperative fibrosis, influencing the trajectory from normal wound healing to pathological scarring. Advances in understanding the cellular and molecular mechanisms have paved the way for novel diagnostic and therapeutic strategies, with the potential to transform perioperative care. Continued research and adoption of evidence-based guidelines will be essential for optimizing patient outcomes and reducing the burden of postoperative fibrotic complications.